The global demand for Rituximab Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Rituximab is a monoclonal antibody drug used for treating cancers such as non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. It slows down or arrests the growth of cancer cells. It acts in different ways to identify and attack cancer cells by attaching itself to the CD20 protein present in the blood cells affected by cancer. It is not chemotherapy. However, it can be used in chemotherapy and alone as well. Rituximab is also used as a biological therapy for treating rheumatoid arthritis, vasculitis, lupus and dermatomyositis. It alleviates swelling and joint pain. It is administered intravenously, and its pill form is not available.
Market Dynamics
The global Rituximab market is predicted to witness significant growth during the forecast period. The target market is primarily driven by the increasing incidence of non-Hodgkin's lymphoma (NHL). The rising geriatric population is another major factor driving the market. Other important factors contributing to its market growth are the rise in healthcare expenditure and initiatives taken by the government. Growing investment in biopharmaceutical research & development activities by market players will positively impact the market growth. Furthermore, the market will be favoured by the growth of emerging economies. On the other hand, factors such as strict rules and regulations associated with biosimilar approvals and the prolonged time required for approval may restrain the growth of the Rituximab market during the assessment period.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rituximab. The growth and trends of rituximab industry provide a holistic approach to this study.
Market Segmentation
This section of the rituximab market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Route Of Administration
- Subcutaneous
- Intravenous
- Parenteral
By Application
- Non-Hodgkin'S Lymphoma
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Rituximab market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Rituximab Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the rituximab market include Amgen Inc, Pfizer Inc, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Apotex Inc, and Biocad, and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.